| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_066828a4b6f7a816447cb8ba1bcbb40e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-974
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6424
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6429
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate |
1996-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14ec16aad101c684fcd4e58dd4a5abcf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70ea23da23616034046c70fe5f218b27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51f93030b9a21a2068bfb16a9935abb9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c668f4cc1e3bbe92a53f8ddb85d03047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ec0861aa1f5fed95c62a2dd76d8e09b |
| publicationDate |
1996-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2224634-A1 |
| titleOfInvention |
Prothrombin derivatives |
| abstract |
The invention relates to novel prothrombin mutants or derivatives thereof having one or more changes in the protein sequence as against the natural protein, are either inactive or have an activity of 10 % at the most and preferably no more than 0.25 % of the natural protein and have a bonding capacity to natural ligands (natural or artificial anticoagulants) essentially corresponding to that of the natural protein. The description also relates to the use of mutated prothrombin mutants or derivatives as pharmaceutical preparations. |
| priorityDate |
1995-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |